Stockscreener 앱 받기
29.35
0.86%
0.25
시간 외 거래:
28.90
-0.45
-1.53%
전일 마감가:
$29.10
열려 있는:
$29.15
하루 거래량:
590.74K
Relative Volume:
0.52
시가총액:
$2.58B
수익:
$218.71M
순이익/손실:
$-113.70M
주가수익비율:
-22.52
EPS:
-1.3034
순현금흐름:
$-73.47M
1주 성능:
+3.64%
1개월 성능:
-4.49%
6개월 성능:
-18.20%
1년 성능:
+55.95%
1일 변동 폭
$28.58
$29.50
1주일 범위
$28.56
$29.90
52주 변동 폭
$18.77
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
명칭
Ideaya Biosciences Inc
전화
650-443-6209
주소
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
29.35 | 2.56B | 218.71M | -113.70M | -73.47M | -1.3034 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-09-18 | 개시 | Guggenheim | Buy |
| 2025-09-04 | 개시 | Barclays | Overweight |
| 2025-09-04 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-07-22 | 개시 | TD Cowen | Buy |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-06-26 | 개시 | Wells Fargo | Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-11-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2024-03-08 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | SVB Securities | Outperform |
| 2023-05-24 | 개시 | Goldman | Buy |
| 2023-04-24 | 업그레이드 | Stifel | Hold → Buy |
| 2023-03-23 | 개시 | Berenberg | Buy |
| 2023-02-28 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-28 | 개시 | CapitalOne | Overweight |
| 2022-10-27 | 개시 | Citigroup | Buy |
| 2022-08-15 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-10 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-03-11 | 개시 | Guggenheim | Buy |
| 2020-10-07 | 개시 | Wedbush | Outperform |
| 2020-09-01 | 개시 | Northland Capital | Outperform |
| 2020-07-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-06 | 개시 | H.C. Wainwright | Buy |
| 2020-03-13 | 개시 | ROTH Capital | Buy |
| 2019-10-17 | 개시 | Oppenheimer | Outperform |
| 2019-09-10 | 개시 | Robert W. Baird | Outperform |
| 2019-06-17 | 개시 | Citigroup | Buy |
| 2019-06-17 | 개시 | JP Morgan | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
모두보기
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference - BioSpace
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing - inkl
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $50 to $78 - Moomoo
Which Is a Better Investment, IDEAYA Biosciences, Inc. or Zymeworks Inc. Stock? - AAII
IDEAYA posts melanoma trial gains, prepares NDA submission - MSN
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data - MarketBeat
Janus Henderson holds 7.27M IDEAYA shares (NASDAQ: IDYA) - Stock Titan
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology - GlobeNewswire
Ideaya Biosciences stock (US45166A1025): Minor price dip amid biotech hiring push - AD HOC NEWS
Precision Trading with Ideaya Biosciences Inc. (IDYA) Risk Zones - Stock Traders Daily
Ideaya Biosciences stock (US45166A1025): Positioned in iShares Genomics ETF holdings - AD HOC NEWS
Time To Worry? Analysts Are Downgrading Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Outlook - Moomoo
Vanguard Group Inc. Buys 97,116 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
Assessing IDEAYA Biosciences (IDYA) Valuation After Positive Darovasertib Phase 2/3 Results And FDA Real-Time Review - Yahoo Finance
Some Analysts Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Estimates - simplywall.st
IDEAYA Biosciences, Inc. (IDYA) reports Q1 loss, misses revenue estimates - MSN
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $53 - Moomoo
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65 - Moomoo
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $53 to $65 - Moomoo
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $50 - Moomoo
IDYA SEC FilingsIdeaya Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Which Is a Better Investment, AnaptysBio, Inc. or IDEAYA Biosciences, Inc. Stock? - AAII
TD Cowen Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating - Moomoo
IDEAYA Biosciences Files New Shelf Registration Statement - TipRanks
IDEAYA Biosciences, Inc. Files Form 8-K SEC Report for May 5, 2026 – Company Information and Common Stock Details - Minichart
Ideaya Biosciences IncEnters Sales Agreement With Jefferies For Common Stock Offering Up To $350 MillionSEC Filing - TradingView
Ideaya Biosciences Inc Files For Mixed Shelf Offering, Size Not Disclosed- SEC Filing - TradingView
IDEAYA (NASDAQ: IDYA) renews shelf, keeps $156.6M ATM capacity - Stock Titan
IDEAYA (NASDAQ: IDYA) has $156.55M ATM capacity remaining under Jefferies sales pact - Stock Titan
IDEAYA (NASDAQ: IDYA) files shelf to sell common stock, debt and warrants - Stock Titan
IDEAYA (NASDAQ: IDYA) reports Q1 loss but holds $972.9M cash - Stock Titan
IDEAYA Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
IDEAYA Biosciences 1Q Loss $98.5M >IDYA - Moomoo
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q1 Revenue $6.6M, vs. FactSet Est of $5.0M - marketscreener.com
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs (PR Newswire) - Aktiellt
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q1 Revenue $6.6M, Vs. FactSet Est of $5.0M - Moomoo
IDYA: Darovasertib met key endpoints in mUM, driving NDA plans and robust pipeline momentum - TradingView
IDEAYA (IDYA) posts Q1 2026 loss, advances darovasertib NDA plan - Stock Titan
IDEAYA says eye cancer drug combo cut progression risk 58% - Stock Titan
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Quantisnow
Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now? - Insider Monkey
Technical Reactions to IDYA Trends in Macro Strategies - Stock Traders Daily
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
IDEAYA Biosciences, Inc. $IDYA Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Five new IDEAYA hires receive stock options at $29.10 a share - Stock Titan
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62 - Moomoo
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program - BioSpace
IDEAYA Biosciences to Initiate New Drug Application Submission f - GuruFocus
Ideaya Biosciences Inc (IDYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):